The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
IMGN632 is a CD123-targeting antibody-drug conjugate comprising a novel humanized anti-CD123 antibody coupled, via a peptide linker, to a unique DNA-alkylating payload of the recently developed IGN (indolinobenzodiazepine pseudodimer) class of cytotoxic compounds. In preclinical studies, IMGN632 displayed antileukemic activity in acute myeloid leukemia (AML) models.
At the 60th American Society of Hematology Annual Meeting & Exposition, Naval Daver from the MD Anderson Cancer Center, Houston, US, presented data from an ongoing first-in-human phase I dose-escalation study (NCT03386513), evaluating the safety and anti-leukemic activity of IMGN632, in patients with relapsed/refractory (R/R) AML or other CD123+ hematologic malignancies. The primary objectives of this ongoing phase I study were to determine the maximum tolerated dose and the recommended Phase 2 dose of IMGN632 when administered as a single agent. The secondary objectives included dose-limiting toxicity (DLT), safety, pharmacokinetics, pharmacodynamics, and preliminary antileukemic activity of IMGN632.
In this phase I study, 33 patients (median age = 70 years; range: 40–80) with CD123+ R/R AML (n = 30) or blastic plasmacytoid dendritic cell neoplasm (BPDCN; n = 3) with no more than three lines of prior therapy were enrolled. IMGN632 was administered intravenously every three weeks (Q3W) using a standard 3+3 design. The starting dose of IMGN632 was 0.015 mg/kg, with escalation following a modified Fibonacci schema. Doses between 0.015–0.45 mg/kg were explored with four doses expanded for further efficacy and safety assessment. Patients received a median of two Q3W IMGN632 doses (range, 1–6).
In summary, IMGN632 demonstrates an initial safety and anti-leukemic activity in patients with R/R AML. Enrollment into the expansion cohorts and the use of fractionated doses is ongoing.
References